• For investors considering whether Cardinal Health's share price still offers value after a strong multi year run, this article explains what the current market price could be implying about the stock.
• The stock last closed at US$185.28, with returns of 27.2% over 1 year, 129.5% over 3 years and 270.6% over 5 years. This comes despite 7 day, 30 day and year to date returns of 3.9%, 12.9% and 9.9% declines respectively.
• Recent coverage around Cardinal Health has focused on its role as a major healthcare distributor, its position within the broader US healthcare system and ongoing interest in large scale providers as investors reassess sector risk. This context has kept attention on how resilient Cardinal Health might be through different industry cycles.
• Simply Wall St assigns Cardinal Health a value score of 3 out of 6. The article next compares different valuation methods before finishing with a way to think about value that goes beyond any single model.

Approach 1: Cardinal Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the cash the company may generate in the future and discounting those cash flows back to today.

For Cardinal Health, the 2 Stage Free Cash Flow to Equity model starts with last twelve months free cash flow of about $4.40b. Analyst inputs and subsequent Simply Wall St extrapolations suggest annual free cash flow projections such as $3.01b in 2026, $3.39b in 2027 and $4.28b in 2030, all expressed in $. These figures are then discounted back using a required return rate to reflect the time value of money and risk.

On this basis, the model arrives at an estimated intrinsic value of about $466.19 per share, compared with the recent share price of $185.28. That gap implies the stock is 60.3% undervalued under these specific DCF assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Cardinal Health is undervalued by 60.3%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Cardinal Health Price vs Earnings

For a profitable company, the P/E ratio is a useful way to see how much investors are paying for each dollar of earnings. It ties directly to bottom line profitability, which is usually more stable than revenue alone and more comparable across businesses than balance sheet values.

What counts as a "fair" P/E depends on how the market views a stock's growth outlook and risk. Higher expected growth or lower perceived risk can support a higher P/E, while slower growth or higher risk usually points to a lower multiple. Cardinal Health currently trades on a P/E of 27.91x. That is above the Healthcare industry average of 22.13x and above the peer average of 19.15x.

Simply Wall St's Fair Ratio for Cardinal Health is 27.09x. This is a proprietary estimate of the P/E that might be expected given factors such as earnings growth, profit margins, industry, market cap and key risks. Because it adjusts for these company specific features, it can be more tailored than a simple comparison with industry or peer averages. With the current P/E only slightly above the Fair Ratio, the stock appears close to fairly valued on this measure.

Result: ABOUT RIGHT

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Cardinal Health Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story about Cardinal Health to the numbers by linking your view on its future revenue, earnings and margins to a financial forecast, a fair value, and a simple comparison with the current share price.

A Narrative is your concise explanation of what you think is driving Cardinal Health, such as expansion in pharmaceuticals and specialty distribution or pressure from regulation and competition. It is paired with the assumptions you think are reasonable for growth, margins, discount rate and P/E, all captured in an easy tool on the Community page that is used by millions of investors.

Because Narratives are updated when new information such as earnings, news about Actinium 225 capacity, analyst target changes or share repurchases comes through, you can quickly see how your fair value moves and decide whether the gap between price and your fair value suggests Cardinal Health looks more attractive or more fully priced to you.

For example, one investor might build a Cardinal Health Narrative close to the higher analyst fair value of about US$275 if they focus on specialty and at home healthcare growth. Another might anchor nearer US$200 if they place more weight on risks such as tariffs, reimbursement changes and major customer dependence, and the Community page lets you compare these views side by side.

Do you think there's more to the story for Cardinal Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.